Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study)

다국어 초록 (Multilingual Abstract)

Background: Osteoprotegerin is an important regulator of bone metabolism and vascular calcification. The association between serum osteoprotegerin level and chronic kidney disease (CKD) progression has not been elucidated. We investigated the prognostic value of serum osteoprotegerin levels in nondialysis CKD patients. Methods: We analyzed 2,082 patients enrolled in the Korean Cohort Study for Outcomes in Patients with CKD between 2011 and 2016. Patients were divided into quartiles by their serum osteoprotegerin levels. The primary outcome was the occurrence of ≥1 of the following: dialysis initiation, kidney transplantation, a two-fold increase in serum creatinine level from baseline, or a 50% decrease in the estimated glomerular filtration rate (eGFR). Cox proportional hazard regression models were used to investigate the prognostic value of the serum osteoprotegerin level to CKD progression. Results: The median follow-up period was 48.9 months, and 641 patients (30.8%) experienced the primary outcome. The hazard ratio of serum osteoprotegerin for renal progression in the full extended Cox proportional hazard model was 1.064 (95% confidence interval, 1.041-1.088). Subgroup analyses by age, presence of diabetes, and eGFR showed significant results consistent with the overall analysis results.Conclusion: Serum osteoprotegerin level is independently associated with renal prognosis and could have prognostic importance in CKD progression.

참고문헌 (Reference)

1 Bucay N, "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification" 12 : 1260-1268, 1998

2 Covic A, "Vascular calcification in chronic kidney disease" 119 : 111-121, 2010

3 Hofbauer LC, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption" 15 : 2-12, 2000

4 Demer L, "The bone-vascular axis in chronic kidney disease" 19 : 349-353, 2010

5 Meng XM, "TGF-β : the master regulator of fibrosis" 12 : 325-338, 2016

6 Jono S, "Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease" 106 : 1192-1194, 2002

7 Papadopouli AE, "Role of OPG/RANKL/RANK axis on the vasculature" 23 : 497-506, 2008

8 Altinova AE, "Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes" 71 : 340-343, 2011

9 Collin-Osdoby P, "Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin" 95 : 1046-1057, 2004

10 Silva I, "Rank/Rankl/opg : literature review" 36 : 209-218, 2011

11 Greene T, "Randomized and observational studies in nephrology : how strong is the evidence?" 53 : 377-388, 2009

12 R Core Team, "R: A language and environment for statistical computing" R Foundation for Statistical Computing

13 Ueland T, "Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction" 44 : 1970-1976, 2004

14 Jorsal A, "Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy" 51 : 2100-2107, 2008

15 Morena M, "Plasma osteoprotegerin is associated with mortality in hemodialysis patients" 17 : 262-270, 2006

16 Elsamahy MH, "Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria" 29 : 563-567, 2015

17 Van Campenhout A, "Osteoprotegerin, vascular calcification and atherosclerosis" 204 : 321-329, 2009

18 Sato T, "Osteoprotegerin levels before and after renal transplantation" 38 (38): S175-S177, 2001

19 Bennett BJ, "Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice" 26 : 2117-2124, 2006

20 Svensson M, "Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients : follow-up data from the ALERT study" 27 : 2571-2575, 2012

21 Venuraju SM, "Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity" 55 : 2049-2061, 2010

22 Morena M, "Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis : potential partners in vascular calcifications" 30 : 1345-1356, 2015

23 Simonet WS, "Osteoprotegerin : a novel secreted protein involved in the regulation of bone density" 89 : 309-319, 1997

24 Klejna K, "OPG/RANK/RANKL signaling system and its significance in nephrology" 47 : 199-206, 2009

25 Pedersen AB, "Missing data and multiple imputation in clinical epidemiological research" 9 : 157-166, 2017

26 Van Buuren S, "Mice : multivariate imputation by chained equations in R" 45 : 1-67, 2011

27 Keith DS, "Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization" 164 : 659-663, 2004

28 Manjunath G, "Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community" 41 : 47-55, 2003

29 Oh KH, "KNOW-CKD(KoreaN cohort study for Outcome in patients With Chronic Kidney Disease) : design and methods" 15 : 80-, 2014

30 Mihai S, "Inflammation-related patterns in the clinical staging and severity assessment of chronic kidney disease" 2019 : 1814304-, 2019

31 Matsubara K, "Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease" 22 : 774-782, 2009

32 Vaccarezza M, "Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats" 3 : 387-391, 2007

33 Suzuki D, "In situ hybridization of interleukin 6 in diabetic nephropathy" 44 : 1233-1238, 1995

34 김경민 ; 오형중 ; 최형윤 ; 이하정 ; 류동열, "Impact of chronic kidney disease on mortality: A nationwide cohort study" 대한신장학회 38 (38): 382-390, 2019

35 Wiley SR, "Identification and characterization of a new member of the TNF family that induces apoptosis" 3 : 673-682, 1995

36 Lewis JR, "Elevated osteoprotegerin predicts declining renal function in elderly women : a 10-year prospective cohort study" 39 : 66-74, 2014

37 Unruh M, "Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study" 66 : 355-366, 2004

38 Omland T, "Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes" 51 : 627-633, 2008

39 Bernardi S, "Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients" 18 : 219-, 2017

40 Go AS, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization" 351 : 1296-1305, 2004

41 Hruska KA, "Cardiovascular risk in chronic kidney disease(CKD) : the CKD-mineral bone disorder(CKD-MBD)" 25 : 769-778, 2010

42 Morena M, "Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients" 7 : e36175-, 2012

43 Scialla JJ, "Biomarkers of vascular calcification and mortality in patients with ESRD" 9 : 745-755, 2014

44 Aoki A, "Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes" 12 : 11-, 2013

45 Levey AS, "A new equation to estimate glomerular filtration rate" 150 : 604-612, 2009